Clinical trials: Idiopathic Pulmonary Fibrosis
- Condition Idiopathic Pulmonary Fibrosis
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Asthma, Chronic Obstructive Pulmonary Disease
A Study of Patients With Chronic Disease
TARGET-RWE is a 10-year, international, longitudinal, observational study of patients with chronic disease designed to specifically address important clinical questions that remain incompletely answered from registration trials.
- Conditions
- Asthma, Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis, IPF
- Trial name
- NCT04263727
- Where
- 5 sites in United States
- Volunteers
- 579 people
- Sponsor
- Target PharmaSolutions, Inc.
Idiopathic Pulmonary Fibrosis
Post Marketing Surveillance of PIRESPA® TAB 200mg (Pirfenidone) for Evaluating the Safety and Efficacy
Post-marketing surveillance of Pirfenidone
- Trial name
- NCT03761082
- Testing
- NA(observation study)
- Volunteers
- 258 people
- Sponsor
- IlDong Pharmaceutical Co Ltd
Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis
An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPF
Open-label therapy will be administered to up to 220 patients, following completion of either InterMune Protocol GIPF-002 Part B or Protocol GIPF-004, to assess the long-term safety of subcutaneous Interferon gamma-1b.
- Conditions
- Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis, Lung Disease
- Trial name
- NCT00076635
- Testing
- Interferon gamma-1b
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- InterMune
Idiopathic Pulmonary Fibrosis
Real-life-persistence to Antifibrotic Treatments
This study will help to better understand the persistence rate to antifibrotic (AF) treatment in real life in France and to identify potential areas for improvement by investigating the factors associated with a non-persistence…
- Trial name
- REPEAT (NCT06485635)
- Testing
- Nintedanib, Pirfenidone
- Where
- France
- Volunteers
- 10,646 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
Efficacy, Safety and Tolerability of NP-120 on Idiopathic Pulmonary Fibrosis and Its Associated Cough
NP-120 (Ifenprodil) has been shown to mediate anti-inflammatory responses and reduce pulmonary fibrosis in a murine model of Idiopathic Pulmonary Fibrosis (IPF).
- Trial name
- NCT04318704
- Testing
- Ifenprodil
- Where
- 6 sites in Australia, New Zealand
- Volunteers
- 20 people
- Sponsor
- Algernon Pharmaceuticals
Idiopathic Pulmonary Fibrosis
Clinical Progression of Mild to Moderate Idiopathic Pulmonary Fibrosis (IPF) Under a Therapy With Esbriet® (Pirfenidone)
The purpose of the study was to assess the clinical outcome of patients with a mild to moderate IPF after a one-year therapy with Esbriet® (Pirfenidone).
- Trial name
- NCT02622477
- Testing
- Pirfenidone
- Where
- 17 sites in Germany
- Volunteers
- 12 people
- Sponsor
- Hoffmann-La Roche
Idiopathic Pulmonary Fibrosis
A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
This study will evaulate the long-term safety, efficacy and pharmacokinetics (PK) of recombinant human pentraxin-2 (rhPTX-2; PRM-151) zinpentraxin alfa, administered by intravenous (IV) infusion to participants with idiopathic…
- Trial name
- STARSCAPE-OLE (NCT04594707)
- Testing
- PRM-151 (Zinpentraxin Alfa)
- Where
- 248 sites in United States, Argentina and 26 more
- Volunteers
- 117 people
- Sponsor
- Hoffmann-La Roche
Idiopathic Pulmonary Fibrosis
Safety and Effectiveness of Nintedanib in Korean Patients
The objectives of this study are to monitor the safety and effectiveness of Ofev in Korean patients in a routine clinical practice setting.
- Trial name
- NCT04525547
- Testing
- Nintedanib
- Where
- 22 sites in South Korea
- Volunteers
- 70 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Fibrosis
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
The purpose of this study is to evaluate the long-term safety and tolerability of Admilparant in participants who completed participation in parent studies IM027-068 (for idiopathic pulmonary fibrosis (IPF)) and IM027-1015 (for…
- Trial name
- NCT07441408
- Testing
- BMS-986278
- Where
- 275 sites in United States, Argentina and 25 more
- Volunteers
- 2,380 people
- Sponsor
- Bristol-Myers Squibb
Idiopathic Pulmonary Fibrosis
All-Case Surveillance of Ofev in Patients With IPF in Japan
This is a non-interventional study based on new data collection to gather real-world information (i.e., data under routine medical practice) on safety and effectiveness of the Ofev® Capsules treatment.
- Trial name
- NCT02607722
- Testing
- Nintedanib
- Where
- Japan
- Volunteers
- 10,117 people
- Sponsor
- Boehringer Ingelheim
Cough, Asthma
Validation of the C-mo System - Cough Monitoring
The goal of this clinical study is to validate C-mo System's ability to automatically detect and characterise cough, in patients over 2 years old with cough as a key or refractory symptom.
- Conditions
- Cough, Asthma, Chronic Obstructive Pulmonary Disease, Gastro Esophageal Reflux
- Trial name
- C-mo_01 (NCT05989698)
- Testing
- C-mo System
- Where
- 8 sites in Portugal
- Volunteers
- 300 people
- Sponsor
- Cough Monitoring Medical Solutions
Idiopathic Pulmonary Fibrosis
Evaluation of Long-Term Safety of Pirfenidone (Esbriet) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
This single arm, post-authorisation study is designed to evaluate the long-term safety of pirfenidone in participants with IPF. The enrolment of participants will be completed within approximately 24 months.
- Trial name
- NCT02699879
- Testing
- Pirfenidone
- Where
- 106 sites in Austria, Denmark and 8 more
- Volunteers
- 1,009 people
- Sponsor
- Hoffmann-La Roche